USP1 inhibition induces single strand DNA gap accumulation and overcomes PARP inhibitor resistance in BRCA1 deficient cancer cells

被引：0
|
作者：
da Costa, Alexandre A. B. A.
Somuncu, Ozge
Ravindranathan, Ramya
Mukkavalli, Sirisha
Martignetti, David B.
Nguyen, Huy
Jiao, Yuqing
Lamarre, Benjamin
Moreau, Lisa
Liu, Joyce
Iyer, Divya
Lazaro, Jean-Bernard
Shapiro, Geoffrey I.
Parmar, Kalindi
D'Andrea, Alan D.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 01期
关键词：
D O I：
10.1158/1538-7445.DNAREPAIR24-B032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B032
引用
收藏
页数：2
相关论文
共 50 条
  • [31] An RNF168 fragment defective for focal accumulation at DNA damage is proficient for inhibition of homologous recombination in BRCA1 deficient cells
    Munoz, Meilen C.
    Yanez, Diana A.
    Stark, Jeremy M.
    NUCLEIC ACIDS RESEARCH, 2014, 42 (12) : 7720 - 7733
  • [32] Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
    Kimbung, Siker
    Biskup, Ewa
    Johansson, Ida
    Aaltonen, Kristina
    Ottosson-Wadlund, Astrid
    Gruvberger-Saal, Sofia
    Cunliffe, Heather
    Fadeel, Bengt
    Loman, Niklas
    Berglund, Pontus
    Hedenfalk, Ingrid
    CANCER LETTERS, 2012, 319 (02) : 232 - 241
  • [33] Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
    Anita K. Mehta
    Emily M. Cheney
    Christina A. Hartl
    Constantia Pantelidou
    Madisson Oliwa
    Jessica A. Castrillon
    Jia-Ren Lin
    Katie E. Hurst
    Mateus de Oliveira Taveira
    Nathan T. Johnson
    William M. Oldham
    Marian Kalocsay
    Matthew J. Berberich
    Sarah A. Boswell
    Aditi Kothari
    Shawn Johnson
    Deborah A. Dillon
    Mikel Lipschitz
    Scott Rodig
    Sandro Santagata
    Judy E. Garber
    Nadine Tung
    José Yélamos
    Jessica E. Thaxton
    Elizabeth A. Mittendorf
    Peter K. Sorger
    Geoffrey I. Shapiro
    Jennifer L. Guerriero
    Nature Cancer, 2021, 2 : 66 - 82
  • [34] Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
    Mehta, Anita K.
    Cheney, Emily M.
    Hartl, Christina A.
    Pantelidou, Constantia
    Oliwa, Madisson
    Castrillon, Jessica A.
    Lin, Jia-Ren
    Hurst, Katie E.
    de Oliveira Taveira, Mateus
    Johnson, Nathan T.
    Oldham, William M.
    Kalocsay, Marian
    Berberich, Matthew J.
    Boswell, Sarah A.
    Kothari, Aditi
    Johnson, Shawn
    Dillon, Deborah A.
    Lipschitz, Mikel
    Rodig, Scott
    Santagata, Sandro
    Garber, Judy E.
    Tung, Nadine
    Yelamos, Jose
    Thaxton, Jessica E.
    Mittendorf, Elizabeth A.
    Sorger, Peter K.
    Shapiro, Geoffrey I.
    Guerriero, Jennifer L.
    NATURE CANCER, 2021, 2 (01) : 66 - +
  • [35] ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2-/- Ovarian Cancer Cells
    Liu, Lu
    Cai, Shurui
    Han, Chunhua
    Banerjee, Ananya
    Wu, Dayong
    Cui, Tiantian
    Xie, Guozhen
    Zhang, Junran
    Zhang, Xiaoli
    McLaughlin, Eric
    Yin, Ming
    Backes, Floor J.
    Chakravarti, Arnab
    Zheng, Yanfang
    Wang, Qi-En
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (01) : 199 - 210
  • [36] PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
    Yin, Linglong
    Liu, Youhong
    Peng, Yuchong
    Peng, Yongbo
    Yu, Xiaohui
    Gao, Yingxue
    Yuan, Bowen
    Zhu, Qianling
    Cao, Tuoyu
    He, Leye
    Gong, Zhicheng
    Sun, Lunquan
    Fan, Xuegong
    Li, Xiong
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [37] PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
    Linglong Yin
    Youhong Liu
    Yuchong Peng
    Yongbo Peng
    Xiaohui Yu
    Yingxue Gao
    Bowen Yuan
    Qianling Zhu
    Tuoyu Cao
    Leye He
    Zhicheng Gong
    Lunquan Sun
    Xuegong Fan
    Xiong Li
    Journal of Experimental & Clinical Cancer Research, 37
  • [38] KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors
    Cadzow, L.
    Gokhale, P. C.
    Ganapathy, S.
    Sullivan, P.
    Nayak, S.
    Shenker, S.
    Schlabach, M.
    Tobin, E.
    Matulonis, U. A.
    Liu, J. F.
    Stegmeier, F.
    Wylie, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S37 - S38
  • [39] Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells
    Farkkila, Anniina
    Rodriguez, Alfredo
    Oikkonen, Jaana
    Gulhan, Doga C.
    Huy Nguyen
    Dominguez, Julieta
    Ramos, Sandra
    Mills, Caitlin E.
    Perez-Villatoro, Fernando
    Lazaro, Jean-Bernard
    Zhou, Jia
    Clairmont, Connor S.
    Moreau, Lisa A.
    Park, Peter J.
    Sorger, Peter K.
    Hautaniemi, Sampsa
    Frias, Sara
    D'Andrea, Alan D.
    CANCER RESEARCH, 2021, 81 (10) : 2774 - 2787
  • [40] DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors
    Wang, Taixiang
    Kyle, Alastair H.
    Baker, Jennifer H. E.
    Liu, Nannan A.
    Banath, Judit P.
    Teymori, Sevin
    Minchinton, Andrew I.
    DNA REPAIR, 2024, 139
12345